The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received
Open accessAbstract
BACKGROUND: Breast cancer is heterogeneous and the existing prognostic classifiers are limited in accuracy, leading to unnecessary treatment of numerous women. B-cell lymphoma 2 (BCL2), an antiapoptotic protein, has been proposed as a prognostic marker, but this effect is considered to relate to oestrogen receptor (ER) status. This study aimed to test the clinical validity of BCL2 as an independent prognostic marker. METHODS: Five studies of 11 212 women with early-stage breast cancer were analysed. Individual patient data included tumour size, grade, lymph node status, endocrine therapy, chemotherapy and mortality. BCL2, ER, progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) levels were determined in all tumours. A Cox model incorporating the time-dependent effects of each variable was used to explore the prognostic significance of BCL2. RESULTS: In univariate analysis, ER, PR and BCL2 positivity was associated with improved survival and HER2 positivity with inferior survival. For ER and PR this effect was time dependent, whereas for BCL2 and HER2 the effect persisted over time. In multivariate analysis, BCL2 positivity retained independent prognostic significance (hazard ratio (HR) 0.76, 95% confidence interval (CI) 0.66-0.88, P<0.001). BCL2 was a powerful prognostic marker in ER- (HR 0.63, 95% CI 0.54-0.74, P<0.001) and ER+ disease (HR 0.56, 95% CI 0.48-0.65, P<0.001), and in HER2- (HR 0.55, 95% CI 0.49-0.61, P<0.001) and HER2+ disease (HR 0.70, 95% CI 0.57-0.85, P<0.001), irrespective of the type of adjuvant therapy received. Addition of BCL2 to the Adjuvant! Online prognostic model, for a subset of cases with a 10-year follow-up, improved the survival prediction (P=0.0039). CONCLUSIONS: BCL2 is an independent indicator of favourable prognosis for all types of early-stage breast cancer. This study establishes the rationale for introduction of BCL2 immunohistochemistry to improve prognostic stratification. Further work is now needed to ascertain the exact way to apply BCL2 testing for risk stratification and to standardise BCL2 immunohistochemistry for this application.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Tissue microarrays for high-throughput molecular profiling of tumor specimens
Kononen, J., Bubendorf, L., Kallionimeni, A., Bärlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,099
Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W., Cronin, M., Baehner, F. L., Watson, D., Bryant, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7985 · Cited by 2,579
Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2364 · Cited by 2,217
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji237 · Cited by 2,162
Tsujimoto, Y., Finger, L. R., Yunis, J., Nowell, P. C., & Croce, C. M. (1984) · Science · doi:10.1126/science.6093263 · Cited by 1,769
Adjuvant Radiotherapy and Chemotherapy in Node-Positive Premenopausal Women with Breast Cancer
Ragaz, J., Jackson, S. M., Le, N., Plenderleith, I. H., Spinelli, J. J., Basco, V. E., Wilson, K. S., Knowling, M. A., Coppin, C. M. L., Paradis, M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710023371402 · Cited by 1,745
The Bcl-2 family: roles in cell survival and oncogenesis
Cory, S., Huang, D. C. S., & Adams, J. M. (2003) · Oncogene · doi:10.1038/sj.onc.1207102 · Cited by 1,463
Pepe, M. S. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh101 · Cited by 1,276
Ragaz, J., Olivotto, I. A., Spinelli, J. J., Phillips, N., Jackson, S. M., Wilson, K. S., Knowling, M. A., Coppin, C. M. L., Weir, L., Gelmon, K., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh297 · Cited by 1,027
Self-citationRavdin, P. M., Siminoff, L. A., Davis, G. J., Mercer, M. B., Hewlett, J., Gerson, N., & Parker, H. L. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.980 · Cited by 996
Desmedt, C., Piette, F., Loi, S., Wang, Y., Lallemand, F., Haibe-Kains, B., Viale, G., Delorenzi, M., Zhang, Y., d'Assignies, M. S., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2765 · Cited by 968
Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers
Hayes, D. F., Bast, R. C., Desch, C. E., Fritsche, H., Kemeny, N. E., Jessup, J. M., Locker, G. Y., Macdonald, J. S., Mennel, R. G., Norton, L., et al. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.20.1456 · Cited by 748
A prognostic index in primary breast cancer
Haybittle, J. L., Blamey, R. W., Elston, C. W., Johnson, J., Doyle, P. J., Campbell, F. C., Nicholson, R. I., & Griffiths, K. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.62 · Cited by 699
Development of the 21-Gene Assay and Its Application in Clinical Practice and Clinical Trials
Sparano, J. A., & Paik, S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.1068 · Cited by 617
Abd El‐Rehim, D. M., Ball, G., Pinder, S. E., Rakha, E., Paish, C., Robertson, J. F. R., Macmillan, D., Blamey, R. W., & Ellis, I. O. (2005) · International Journal of Cancer · doi:10.1002/ijc.21004 · Cited by 606
Self-citationPaik, S., Hazan, R., Fisher, E. R., Sass, R. E., Fisher, B., Redmond, C., Schlessinger, J., Lippman, M. E., & King, C. R. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.1.103 · Cited by 594
Expression of luminal and basal cytokeratins in human breast carcinoma
Abd El‐Rehim, D. M., Pinder, S. E., Paish, C. E., Bell, J., Blamey, R., Robertson, J. F., Nicholson, R. I., & Ellis, I. O. (2004) · The Journal of Pathology · doi:10.1002/path.1559 · Cited by 594
Self-citationClinical Application of the 70-Gene Profile: The MINDACT Trial
Cardoso, F., Van't Veer, L., Rutgers, E., Loi, S., Mook, S., & Piccart-Gebhart, M. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.3222 · Cited by 464
Silvestrini, R., Veneroni, S., Daidone, M. G., Benini, E., Boracchi, P., Mezzetti, M., di Fronzo, G., Rilke, F. O., & Veronesi, U. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.7.499 · Cited by 454
The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry.
O'Reilly, L. A., Huang, D. C., & Strasser, A. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb01090.x · Cited by 377
The Melbourne Collaborative Cohort Study.
Giles, G. G., & English, D. R. (2002) · PubMed · Cited by 313
Self-citationChia, S., Norris, B., Speers, C., Cheang, M., Gilks, B., Gown, A. M., Huntsman, D., Olivotto, I. A., Nielsen, T. O., & Gelmon, K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.8659 · Cited by 301
Self-citationYamauchi, H., Stearns, V., & Hayes, D. F. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2334 · Cited by 291
Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7.
Wang, T. T. Y., & Phang, J. M. (1995) · PubMed · Cited by 271
Time-dependence of hazard ratios for prognostic factors in primary breast cancer
Hilsenbeck, S. G., Ravdin, P. M., de Moor, C. A., Chamness, G. C., Osborne, C. K., & Clark, G. M. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006133418245 · Cited by 237 · cited 1×
“Our analysis confirms the previously described time dependence of hormone receptors (ER and PR) as prognostic markers in breast cancer (Hilsenbeck et al, 1998; Anderson et al, 2006).”
BackgroundBcl-2 Is a Prognostic Marker in Breast Cancer Independently of the Nottingham Prognostic Index
Callagy, G. M., Pharoah, P. D., Pinder, S. E., Hsu, F. D., Nielsen, T. O., Ragaz, J., Ellis, I. O., Huntsman, D., & Caldas, C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2719 · Cited by 237
Self-citationCheang, M. C. U., Treaba, D. O., Speers, C. H., Olivotto, I. A., Bajdik, C. D., Chia, S. K., Goldstein, L. C., Gelmon, K. A., Huntsman, D., Gilks, C. B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4155 · Cited by 206
Self-citationMeta-analysis confirms BCL2 is an independent prognostic marker in breast cancer
Callagy, G. M., Webber, M. J., Pharoah, P. D., & Caldas, C. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-153 · Cited by 193
Self-citationParadoxical inhibition of solid tumor cell growth by bcl2.
Pietenpol, J. A., Papadopoulos, N., Markowitz, S. D., et al. (1994) · PubMed · Cited by 185
Molecular Classification of Breast Carcinomas Using Tissue Microarrays
Callagy, G., Cattaneo, E., Daigo, Y., Happerfield, L., Bobrow, L. G., Pharoah, P. D. P., & Caldas, C. (2003) · Diagnostic Molecular Pathology · doi:10.1097/00019606-200303000-00004 · Cited by 171
Self-citationLipponen, P., Pietiläinen, T., Kosma, V., Aaltomaa, S. H., Eskelinen, M., & Syrjäunen, K. (1995) · The Journal of Pathology · doi:10.1002/path.1711770109 · Cited by 156
Prognostic Models: A Methodological Framework and Review of Models for Breast Cancer
Altman, D. G. (2009) · Cancer Investigation · doi:10.1080/07357900802572110 · Cited by 142
bcl-2 and apoptosis in lymph node positive breast carcinoma
Berardo, M. D., Elledge, R. M., de Moor, C., Clark, G. M., Osborne, C. K., & Allred, D. C. (1998) · Cancer · Cited by 130
Anderson, W. F., Chen, B. E., Jatoi, I., & Rosenberg, P. S. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9231-y · Cited by 91
Putting Risk Prediction in Perspective: Relative Utility Curves
Baker, S. G. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp353 · Cited by 83
Allelic association of the human homologue of the mouse modifier Ptprj with breast cancer
Lesueur, F., Pharoah, P. D. P., Laing, S., Ahmed, S., Jordan, C., Smith, P. L., Luben, R., Wareham, N. J., Easton, D. F., Dunning, A. M., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi237 · Cited by 73
Self-citationReading the prognosis of the individual with breast cancer
Blamey, R. W., Pinder, S. E., Ball, G., Ellis, I. O., Elston, C. W., Mitchell, M. J., & Haybittle, J. L. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.01.003 · Cited by 57
Self-citationCharpin, C., Garcia, S., Bonnier, P., Martini, F., Andrac, L., Horschowski, N., Lavaut, M., & Allasia, C. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2025 · Cited by 51
Bcl-2 expression correlates with lymphovascular invasion and long-term prognosis in breast cancer
Neri, A., Marrelli, D., Roviello, F., Marco, G. D., Mariani, F., Stefano, A. D., Megha, T., Caruso, S., Corso, G., Cioppa, T., et al. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9183-2 · Cited by 37
Cited by
Wang, T., Shao, W., Huang, Z., Tang, H., Zhang, J., Ding, Z., & Huang, K. (2021) · Nature Communications · doi:10.1038/s41467-021-23774-w · Cited by 671
Targeting BCL-2 regulated apoptosis in cancer
Campbell, K. J., & Tait, S. W. G. (2018) · Open Biology · doi:10.1098/rsob.180002 · Cited by 545
A fate worse than death: apoptosis as an oncogenic process
Ichim, G., & Tait, S. W. G. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.58 · Cited by 451
Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes
Dai, X., Xiang, L., Li, T., & Bai, Z. (2016) · Journal of Cancer · doi:10.7150/jca.13141 · Cited by 440
A new genome‐driven integrated classification of breast cancer and its implications
Dawson, S., Rueda, O. M., Aparicio, S., & Caldas, C. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.19 · Cited by 306
Self-citation
Metadata
- Authors
- Dawson, S.-J., Makretsov, N., Blows, F. M., Driver, K. E., Provenzano, E., Le Quesne, J., Baglietto, L., Severi, G., Giles, G. G., McLean, C. A., Callagy, G., Green, A. R., Ellis, I., Gelmon, K., Turashvili, G., Leung, S., Aparicio, S., Huntsman, D., Caldas, C., & Pharoah, P.
- Venue
- British Journal of Cancer
- Published
- 2010-07-27
- Volume
- 103
- Issue
- 5
- Pages
- 668-675
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2168362647
- Cited by
- 317
- References
- 43
- FWCI
- 6.41
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.